The use of plasma androstenedione in monitoring therapy of patients with congenital adrenal hyperplasia.
Therapy of congenital adrenal hyperplasia tranditionally is monitored by the amount of urinary 17-KS. However, 24-hour urine collections are difficult to obtain and are often unreliable. Measurement of the plasma concentrations of androgens, such as delta or T, would therefore be a more convenient way to determine the efficacy of treatment. Over a period of 2 to 24 months, 23 patients were periodically assessed by clinical examination, bone age, and determinations of plasma delta, plasma T, and 24-hour urinary 17-KS. Plasma T concentration correlated well with clinical control in females and in preadolescent males, but not in infant and pubertal males. By contrast, plasma delta concentration correlated well with clinical control in either sex, regardless of stage of puberty. The present study suggests that monitoring plasma delta concentration is useful in the long-term management of patients with CAH.
D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D000328:Adult; D000367:Age Factors; D000735:Androstenedione / Q000097:blood*; D002648:Child; D003348:Cortisone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008137:Longitudinal Studies; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012737:Sex Factors; D013739:Testosterone / Q000097:blood
D015068:17-Ketosteroids; D013739:Testosterone; D000735:Androstenedione; D003348:Cortisone; D011241:Prednisone